The Latest Cardiac and Vascular News
BOLT-DVT, a recent prospective, multicenter Investigational Device Exemption (IDE) trial, demonstrated first-line use of computer assisted vacuum thrombectomy (CAVT) for DVT is safe and effective ALAMEDA, Calif., Oct. 20, 2026 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, announced that the U.S. Food and Drug Administration (FDA) […]
MENLO PARK, Calif.–(BUSINESS WIRE)– #EuroIntervention–Jupiter Endovascular announced pivotal trial publication showing that its Vertex Thrombectomy System normalized hemodynamics in 50% of PE patients.
LAS VEGAS, Oct. 14, 2026 /PRNewswire/ — The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announced results from Late-Breaking Clinical Trial sessions at VIVA 2026, held at Bellagio…
Approval brings U.S. vascular surgeons the first on-label bridging stent graft for both fenestrated and branched endovascular aortic repair, as three-year clinical outcomes demonstrate safety and effectiveness. FLAGSTAFF, Ariz., Oct. 14, 2026 /PRNewswire/ — W. L. Gore & Associates’…
Combination of Hēlo Thrombectomy System and Hēlo Return establish the first 510(k)-cleared platform compatible with continuous vacuum aspiration MENLO PARK, Calif., Oct. 12, 2026 /PRNewswire/ — Endovascular Engineering, Inc. (E2), a commercial-stage medical technology company focused on…
CAUTION: Investigational device. Limited by United States law to investigational use. FLAGSTAFF, Arizona/USA (October 1, 2026)—W. L. Gore & Associates’ medical business (Gore) announced today the first patient enrollment in the IBE Plus Pivotal Study, a clinical trial evaluating the investigational GORE® EXCLUDER® IBE Plus Stent Graft for the treatment […]
ALISO VIEJO, Calif., Oct. 7, 2026 /PRNewswire/ — Okami Medical, a medical technology company developing novel vascular embolization solutions, announced today that the U.S. FDA has granted an expanded indication for its LOBO® Vascular Occlusion System. The expanded indication extends the…
Live case showcases successful below-the-knee revascularization with two MOTIV® scaffolds; late-breaking analysis shows higher efficacy endpoint rates with MOTIV versus balloon angioplasty in both Rutherford 4 and Rutherford 5 CLTI populations SAN DIEGO, Oct. 6, 2026 /PRNewswire/ — REVA…
SAN JOSE, Calif.–(BUSINESS WIRE)–Shape Memory Medical Inc., the developer of proprietary volume-expanding shape memory polymer solutions for endovascular embolization, today announced that Brazil’s national health surveillance agency, ANVISA (Agência Nacional de Vigilância Sanitária), has granted authorization for the IMPEDE Embolization Plug, the IMPEDE-FX Embolization Plug, and the IMPEDE-FX RapidFill. The approval process was supported by Biomedical, which acts as Shape Memory Medical’s Br
MIAMI LAKES, Fla.–(BUSINESS WIRE)– #Cordis–Cordis, a global leader in interventional cardiovascular and endovascular technologies, today announced that the SELUTION SLR SUSTANE™ PTA Drug-Eluting Balloon (SUSTANE DEB) achieved the highest reported 12-month primary patency in the SELUTION4SFA US pivotal trial at 90.3%. The results were presented during a Late-Breaking Clinical Trial session at VIVA 2026 by Jay Mathews, MD, MS, Director, Cardiac Catheterization Laboratory, PERT & Structural Heart at
